SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (9366)3/24/1999 7:24:00 PM
From: LarryS  Read Replies (1) | Respond to of 17367
 
I agree, zero deaths for Neuprex would
be almost impossible since this is such
a deadly disease....let's hope for 1/2
the deaths as the placebo arm. That would
be outstanding and anything better would
be a miracle, both for the patients and
our pocketbooks.

Also the way I have understood the discussion
on this board the gentleman that died during
the Phase II trial would not be included in this
trial.



To: aknahow who wrote (9366)3/24/1999 9:31:00 PM
From: Bluegreen  Read Replies (1) | Respond to of 17367
 
George, in my opinion giving a Baboon E.coli IV is more deadly than Meningo. in kids, much more deadly. Now, what percent of Baboons survive this type of assault when given conventional antibiotics AND BPI? Now if one had a Baboon given the above assault with equivalent characteristics as kid that died in Phase II, could the Baboon still be saved?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News